Lixte Biotechnology Files 8-K on Material Agreement
Ticker: LIXT · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1335105
Sentiment: neutral
Topics: material-agreement, corporate-filing, biotechnology
Related Tickers: LIXT
TL;DR
LIXT filed an 8-K on Jan 6, 2025, confirming a material definitive agreement. Offices moved to Pasadena, CA.
AI Summary
On January 6, 2025, Lixte Biotechnology Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing indicates the company's principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101, with a reported phone number of (631) 830-7092. The company is incorporated in Delaware and operates within the Pharmaceutical Preparations sector.
Why It Matters
This filing signals a significant business development for Lixte Biotechnology, potentially impacting its operations and future strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of the agreement is not detailed in this summary.
Key Numbers
- 001-39717 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-2903526 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- January 6, 2025 (date) — Date of Report
- 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 (location) — Principal Executive Offices
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
FAQ
What is the nature of the material definitive agreement filed on January 6, 2025?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
Where are Lixte Biotechnology Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
What is Lixte Biotechnology Holdings, Inc.'s Standard Industrial Classification code?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's SEC file number?
The SEC file number is 001-39717.
When was the company incorporated?
The company is incorporated in Delaware.
Filing Stats: 1,104 words · 4 min read · ~4 pages · Grade level 14.4 · Accepted 2025-01-06 17:23:09
Key Financial Figures
- $0.0001 — g as agent, shares of our common stock, $0.0001 par value per share, having an aggregat
- $1,700,000 — ng an aggregate offering price of up to $1,700,000, subject to the terms and conditions of
- $50,000 — the Agent's legal counsel not to exceed $50,000, plus certain ongoing disbursements of
- $5,000 — isbursements of its legal counsel up to $5,000 per bring down. The offering of share
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex5-1.htm (EX-5.1) — 13KB
- ex10-1.htm (EX-10.1) — 279KB
- 0001493152-25-001069.txt ( ) — 614KB
- lixt-20250106.xsd (EX-101.SCH) — 3KB
- lixt-20250106_def.xml (EX-101.DEF) — 29KB
- lixt-20250106_lab.xml (EX-101.LAB) — 36KB
- lixt-20250106_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan President and Chief Executive Officer INDEX TO EXHIBITS Exhibit No. Description 5.1 Opinion Letter of TroyGould PC 10.1 At-the-Market Sales Agreement dated as of January 6, 2025 between Lixte Biotechnology Holdings, Inc. and WallachBeth Capital, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)